Re:Clinician impact and financial cost to NHS of litigation ...
by cirrus-clouds on Sunday February 25, 2018 @08:31AM
(#16458848)
Another example: anti-cancer drug Avastis has been found to be effective against blindness in old age (wet macular degeneration). The current drug for preventing wet macular degeneration is Lucentis, which costs 10 times more than Avastis.
Twelve NHS clinical commissioning groups (CCGs) have recommended switching to the cheaper (and just as effective) Avastis drug. But Novartis and Bayer, who market the more expensive Lucentis, have threaten legal action over the use of the cheaper drug.
https://www.theguardian.com/society/2017/nov/01/drug-giants-...
Re:Clinician impact and financial cost to NHS of litigation ...
by dm319 on Sunday February 25, 2018 @09:13AM
(#16459027)
And this is the concern of agreements like TTIP, where companies can sue government policies that result in lost revenue.
Obviously there are some benefits - i.e. governments deliberately creating regulations that make competition difficult and essentially recreating protectionism while reaping the rewards of a free market, so I can see why it is a good thing, but it could easily be abused.
In England all prescription info is open. We can use that to try to reduce prescribing of meds that have more effective alternatives, or that have cheaper as effective alternatives, or that are dangerous.
https://openprescribing.net/